Guiling Li

581 total citations
13 papers, 387 citations indexed

About

Guiling Li is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Guiling Li has authored 13 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Guiling Li's work include Ovarian cancer diagnosis and treatment (3 papers), Microbial Natural Products and Biosynthesis (2 papers) and Fungal Biology and Applications (2 papers). Guiling Li is often cited by papers focused on Ovarian cancer diagnosis and treatment (3 papers), Microbial Natural Products and Biosynthesis (2 papers) and Fungal Biology and Applications (2 papers). Guiling Li collaborates with scholars based in China, United States and Ethiopia. Guiling Li's co-authors include Wen‐Jin Su, Jianfeng Wang, Yaojian Huang, Zhonghui Zheng, Zhonghui Zheng, Haihong Wang, Shaofa Nie, Xingjian Xu, Min Liu and Zhengping Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Food Chemistry and International Journal of Environmental Research and Public Health.

In The Last Decade

Guiling Li

12 papers receiving 352 citations

Peers

Guiling Li
Blaise A. Darveaux United States
Lee‐Han Kim South Korea
Valdet Uka Belgium
C. S. Reddy United States
Xiling Zhao United States
Peter K. Chen United States
Guiling Li
Citations per year, relative to Guiling Li Guiling Li (= 1×) peers Sung‐Yuan Hsieh

Countries citing papers authored by Guiling Li

Since Specialization
Citations

This map shows the geographic impact of Guiling Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guiling Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guiling Li more than expected).

Fields of papers citing papers by Guiling Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guiling Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guiling Li. The network helps show where Guiling Li may publish in the future.

Co-authorship network of co-authors of Guiling Li

This figure shows the co-authorship network connecting the top 25 collaborators of Guiling Li. A scholar is included among the top collaborators of Guiling Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guiling Li. Guiling Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Wei, Wei, Yongguo Li, Ai Huang, et al.. (2025). Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy. Molecular Metabolism. 96. 102151–102151. 1 indexed citations
2.
An, Jusheng, Guiling Li, Jennifer Zhang, et al.. (2025). Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907). Gynecologic Oncology. 202. 33–40. 1 indexed citations
3.
Chen, Yu‐Lei, Hua Liu, Guiling Li, et al.. (2025). Synergistic effects of matrix metalloproteinases on the degradation of collagen in abalone (Haliotis discus hannai). Food Chemistry. 473. 143111–143111. 1 indexed citations
6.
Xiong, Fan, Huayi Li, Hong Zheng, et al.. (2024). Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. International Journal of Gynecological Cancer. 34(9). 1461–1465. 3 indexed citations
7.
Li, Huiping, Rutie Yin, Youzhong Zhang, et al.. (2022). A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.. Journal of Clinical Oncology. 40(16_suppl). 5539–5539. 1 indexed citations
8.
Wang, Haihong, et al.. (2018). Angiogenesis Inhibitors for the Treatment of Ovarian Cancer. International Journal of Gynecological Cancer. 28(5). 903–914. 30 indexed citations
9.
Xia, Jing, Xingjian Xu, Guiling Li, et al.. (2014). Evaluating the Effect of a Novel Molluscicide in the Endemic Schistosomiasis Japonica Area of China. International Journal of Environmental Research and Public Health. 11(10). 10406–10418. 23 indexed citations
10.
Li, Guiling, et al.. (2007). The expression levels of endogenous aFGF mRNA in microwave burn wound tissues and its clinical significance. Journal of Huazhong University of Science and Technology [Medical Sciences]. 27(5). 576–578. 1 indexed citations
11.
Li, Zhou, et al.. (2005). [Purification of the effective component from Solanum xanthocarpum and its effect against Oncomelania snails].. PubMed. 23(4). 206–8. 5 indexed citations
12.
Huang, Yaojian, Jianfeng Wang, Guiling Li, Zhonghui Zheng, & Wen‐Jin Su. (2001). Antitumor and antifungal activities in endophytic fungi isolated from pharmaceutical plantsTaxus mairei,Cephalataxus fortuneiandTorreya grandis. FEMS Immunology & Medical Microbiology. 31(2). 163–167. 160 indexed citations
13.
Wang, Jianfeng, et al.. (2000). Taxol fromTuberculariasp. strain TF5, an endophytic fungus ofTaxus mairei. FEMS Microbiology Letters. 193(2). 249–253. 157 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026